G

Glenmark Pharmaceuticals Ltd
NSE:GLENMARK

Watchlist Manager
Glenmark Pharmaceuticals Ltd
NSE:GLENMARK
Watchlist
Price: 1 378.1 INR 0.16% Market Closed
Market Cap: 388.9B INR

During the last 3 months Glenmark Pharmaceuticals Ltd insiders have not bought any shares, and have not sold any shares. The stock price has dropped by 9% over this period (open performance analysis).

The last transaction was made on Sep 20, 2023 by Mr. Praveen D Kurkal (Assistant Vice President of Research and Development) , who sold 852k INR worth of GLENMARK shares.

Last Transactions:
Mr. Praveen D Kurkal
Assistant Vice President of Research and Development
₹-425.5k
Mr. Praveen D Kurkal
Assistant Vice President of Research and Development
₹-852k
Mr. Praveen D Kurkal
Assistant Vice President of Research and Development
₹-852k
Robin Pinto
Vice President - Human Resources
₹+122.5k
Sridhar Gorthi
Independent Director
₹-299.4k
Glenn Mario Saldanha
Chairman and Managing Director
₹+5m
Cherylann Maria Pinto
Non-Executive Non-Independent Director
₹+1m
Glenn Mario Saldanha
Chairman and Managing Director
₹+5m
Glenn Mario Saldanha
Chairman and Managing Director
₹+1.8m
Glenn Mario Saldanha
Chairman and Managing Director
₹+5m
Rayna Marie Saldanha
Company Secretary and Compliance Officer
₹+4.9m
Aisha Louise Saldanha
Independent Director
₹+4.9m
Robin Pinto
Vice President - Human Resources
₹+372.2k
Robin Pinto
Vice President - Human Resources
₹+112.8k
Robin Pinto
Vice President - Human Resources
₹+116.3k
Robin Pinto
Vice President - Human Resources
₹+239.7k
Robin Pinto
Vice President - Human Resources
₹+250.2k
Glenn Mario Saldanha
Chairman and Managing Director
₹+4.8m
Cherylann Maria Pinto
Non-Executive Non-Independent Director
₹+473.9k
Robin Pinto
Vice President - Human Resources
₹+94.6k
Blanche Saldanha
Independent Non-Executive Director
₹+2.9m
Robin Pinto
Vice President - Human Resources
₹+284.5k
Blanche Saldanha
Independent Non-Executive Director
₹+2.8m
Cherylann Maria Pinto
Non-Executive Non-Independent Director
₹+1m
Glenn Mario Saldanha
Chairman and Managing Director
₹+5m
Cherylann Maria Pinto
Non-Executive Non-Independent Director
₹+495.8k
Cherylann Maria Pinto
Non-Executive Non-Independent Director
₹+697.8k
Glenn Mario Saldanha
Chairman and Managing Director
₹+4.7m
Glenn Mario Saldanha
Chairman and Managing Director
₹+295.9k
Cherylann Maria Pinto
Non-Executive Non-Independent Director
₹+1.5m
Glenn Mario Saldanha
Chairman and Managing Director
₹+2m
Glenn Mario Saldanha
Chairman and Managing Director
₹+2.9m
View All Transactions

During the last 3 months Glenmark Pharmaceuticals Ltd insiders have not bought any shares, and have not sold any shares. The stock price has dropped by 9% over this period (open performance analysis).

The last transaction was made on Sep 20, 2023 by Mr. Praveen D Kurkal (Assistant Vice President of Research and Development) , who sold 852k INR worth of GLENMARK shares.

Sold
0-3
months
0 INR
0
3-6
months
0 INR
0
6-9
months
0 INR
0
9-12
months
0 INR
0
Bought
0-3
months
No Insider Transactions
0
0 INR
3-6
months
No Insider Transactions
0
0 INR
6-9
months
No Insider Transactions
0
0 INR
9-12
months
No Insider Transactions
0
0 INR

Glenmark Pharmaceuticals Ltd
Insider Trading Chart

Glenmark Pharmaceuticals Ltd
Insiders Performance

1 Week Later 1 Month Later 3 Months Later 6 Months Later 1 Year Later
Average Return
Median Return
Win Rate

Glenmark Pharmaceuticals Ltd
Last Insider Transactions

Global
Insiders Monitor

Glenmark Pharmaceuticals Ltd
Glance View

Market Cap
388.9B INR
Industry
Pharmaceuticals

Glenmark Pharmaceuticals Ltd., founded in 1977 by Gracias Saldanha, has crafted its journey from a single-product company to a noteworthy player in the global pharmaceutical landscape. Headquartered in Mumbai, India, its growth has been driven by a formidable strategy of focusing on both generics and novel drug discovery. In the fiercely competitive world of pharmaceuticals, Glenmark carved its niche by building a diverse product portfolio that spans across dermatology, respiratory, and oncology segments, among others. The company’s nuanced understanding of therapeutic areas and its pursuit of complex generics have empowered it to not only tap into established markets but also venture into emerging ones across 80 countries. This international strategy, combined with robust research and development infrastructure, underscores how Glenmark leverages scientific innovation to ensure steady revenue streams. At the heart of Glenmark's operations lies its commitment to research-driven growth. The company allocates significant resources to its R&D initiatives, manifesting in state-of-the-art facilities across India, Switzerland, and the U.S. Through these centers, Glenmark focuses on the development of differentiated generic medicines and the discovery of innovative therapeutic molecules. The synergy between its generic and innovative drug segments enables Glenmark to sustain profitability by capitalizing on patent expiries while simultaneously pioneering novel drug therapies. This dual approach not only helps the company secure a competitive position in the pharmaceutical market but also fuels its earnings through a balanced mix of volume-driven sales and premium pricing of differentiated products.

GLENMARK Intrinsic Value
1 029.91 INR
Overvaluation 25%
Intrinsic Value
Price
G

What is Insider Trading?

Insider trading refers to the buying or selling of a company’s stock by individuals with access to non-public, material information about the company.

While legal insider trading occurs when insiders follow disclosure rules, illegal insider trading involves trading based on confidential information and is prohibited by law.

Why is Insider Trading Important?

It isn't a coincidence that corporate executives seem to always buy at the right times. After all, they have access to every bit of company information you could ever want.

However, the fact that company executives have unique insights doesn't mean that individual investors are always left in the dark. Insider trading data is out there for all who want to use it.

Peter Lynch

Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.

Back to Top